Please enable Javascript
Localized Prostate Cancer
Advertisement
Novel Theranostic Radiopharmaceutical Detects Lesions in Patients With PSMA PET-Negative BCR Prostate Cancer
Zachary Bessette
Next-Generation Imaging
|
September 13, 2023
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
Read More
Examining Biochemical Recurrence as a Substitute for Overall Survival in Localized Prostate Cancer
Emily Menendez
Localized Prostate Cancer
|
September 8, 2023
Utilizing BCR as a replacement measurement for OS in patients with localized prostate cancer is a controversial topic.
Read More
Novel Single-Port Approaches to Traditional Multiport Surgeries
Akhil Abraham Saji, MD
Localized Prostate Cancer
|
September 5, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Read More
How Does Performance Status Affect the Efficacy of Systemic Therapy for Prostate Cancer?
Emily Menendez
Prostate Cancer
|
August 2, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Read More
MRI for Prostate Cancer: Background, Current Uses, and Integration With AI
Akhil Abraham Saji, MD
Localized Prostate Cancer
|
July 31, 2023
What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI?
Read More
AI Model Predicts Patients Who Can Benefit From ADT
Emily Menendez
Localized Prostate Cancer
|
July 27, 2023
An AI-based model predicts which patients with localized prostate cancer would better benefit from the use of ADT.
Read More
Dr. Brian Helfand on the SPOTLIGHT Study: Recurrent Prostate Cancer Detection With 18F-rhPSMA-7.3
Brian Helfand, MD, PhD
RLT-PSMA
|
June 26, 2023
Dr. Brian Helfand details the purpose of 18F-rhPSMA-7.3 and how it compares to other PSMA PET radiopharmaceuticals.
View More
Dr. Miron on Kidney Cancer Updates, Molecular Alterations in Intraductal Carcinoma of the Prostate
Benjamin Miron, MD
ASCO 2023
|
June 16, 2023
Dr. Miron provides an overview of clinical implications of molecular alterations in intraductal carcinoma of the prostate.
View More
Drs. Armstrong, Wallis on AI Biomarkers and HRQoL for Localized Prostate Cancer, mCRPC
Andrew Armstrong, MD, MSc
ASCO 2023
|
June 4, 2023
Drs. Armstrong and Wallis discuss the design of an AI-derived pathology-based biomarker for localized high-risk prostate.
View More
More Research Needed to Determine Optimal Management of Complications Due to Salvage Radical Prostatectomy
Akhil Abraham Saji, MD
Localized Prostate Cancer
|
May 30, 2023
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
Read More
Prognostic Impact of PSA Nadir After Radiotherapy, ADT for Localized Prostate Cancer
Zachary Bessette
ASCO 2023
|
May 26, 2023
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
Read More
NCCN Guidelines Influence Community Care, May Result in Less Overdiagnosis of Prostate Cancer
Emily Menendez
Localized Prostate Cancer
|
May 10, 2023
Adherence to the National Comprehensive Cancer Network clinical practice guidelines may lead to better outcomes for patients.
Read More
Evaluating the ProtecT Trial: 15-Year Outcomes After Monitoring, Surgery, or Radiotherapy
David Ambinder, MD
Localized Prostate Cancer
|
April 26, 2023
The recent ProtecT analysis examined 15-year follow-up data on mortality, metastasis-free survival, and disease progression.
Read More
Transcriptomic Profiling Offers Neoadjuvant Therapy Benefits for PCa
Emily Menendez
Localized Prostate Cancer
|
April 12, 2023
Transcriptomic profiling was used to identify predictive biomarkers and determine patient response to docetaxel therapies.
Read More
Enzalutamide Plus Leuprolide Improves Metastasis-Free Survival in Non-metastatic Prostate Cancer
Emily Menendez
Localized Prostate Cancer
|
March 21, 2023
A study arm from the phase 3 EMBARK trial evaluating enzalutamide for nmCSPC with high-risk BCR has had positive outcomes.
Read More
Analyzing 15-Year Follow-up Outcomes After Prostate Cancer Treatment
Emily Menendez
Localized Prostate Cancer
|
March 13, 2023
A recent study analyzed a 15-year follow-up in men with prostate cancer to gauge the effectiveness of different treatments.
Read More
Cost of Localized Prostate Cancer Care Impacts Decision-Making for Clinicians, Patients
Akhil Abraham Saji, MD
Localized Prostate Cancer
|
February 28, 2023
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
Read More
Novel Approaches for Risk Stratifying Newly Diagnosed Localized Prostate Cancer
Phouc T. Tran, MD, PhD
ASCO GU Symposium 2023
|
February 24, 2023
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
View More
Novel Guidelines for PSMA PET Staging of Localized Prostate Cancer
David Nanus, MD
ASCO GU Symposium 2023
|
February 17, 2023
David Nanus, MD, details the ways in which PSMA PET varies in guidelines and is used to stage localized prostate cancer.
View More
MRI-Guided Versus CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer
Emily Menendez
Localized Prostate Cancer
|
January 23, 2023
A recent update on the phase 3 MIRAGE trial determined if MRI or CT-guided stereotactic body radiotherapy is most effective.
Read More
Load More
Advertisement
Advertisement
Advertisement